Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Bristol Myers Squibb (BMY) Stock Fair Value Edges Lower On Split Analyst Views

Analyst downgrade Clinical trial results Regulatory approval AI-generated analysis

πŸ“‰ Simply Wall St lowered BMY's fair value estimate from US$66.71 to US$65.25, citing a reduced long-term revenue growth assumption of 7.39% and a lower P/E multiple of 19.75x.

πŸ”¬ Bullish analysts highlight admilparant as a potential blockbuster for idiopathic pulmonary fibrosis, with Jefferies lifting peak sales estimates and William Blair describing a meaningful market opportunity.

⚠️ Wells Fargo flags liver safety concerns around admilparant as a meaningful overhang that could impact the drug's commercialization and regulatory path.

πŸ“ˆ BMY reported positive Phase 3 data for izalontamab in advanced breast cancer showing a 59% reduction in disease progression risk versus chemotherapy.

πŸ’Š The company received FDA approval support for CELMoD ZENBEXUS in combination with daratumumab and dexamethasone based on MRD negative complete response in multiple myeloma.

πŸ“‰ Interim Phase 1 Breakfree-2 data for zola cel in multiple sclerosis showed early efficacy signals but coincided with a patient death from septic pneumonia, triggering a 2.5% stock decline.

🀝 Bristol-Myers Squibb announced expanded AI and real-world data agreements with Tempus AI and Pathos AI, securing exclusive access to the Pathos Foundry platform in neuroscience.

πŸ“Š Analyst consensus ranges widely from US$40s to US$82, with Piper Sandler, Jefferies, and Guggenheim maintaining constructive targets despite recent trims by Leerink and Morgan Stanley.

🧬 The company's strategy focuses on offsetting pressure from older drugs facing patent cliffs through growth in oncology, neuroscience, and immunology assets like milvexian and Cobenfy.

Bullish Signals
  • Bullish analysts including Piper Sandler, Jefferies, and Guggenheim maintain high price targets up to US$82, citing constructive views on the broader pipeline and potential business development activity.
  • Jefferies lifted its admilparant peak sales estimate, describing it as a potential blockbuster market opportunity for idiopathic pulmonary fibrosis supported by ALOFT-IPF data.
  • Phase 3 ACTION 1 data for radiopharmaceutical RYZ101 in gastroenteropancreatic neuroendocrine tumors provided positive late-stage oncology readouts supporting the company's growth portfolio.
  • The FDA supported approval of CELMoD ZENBEXUS in multiple myeloma based on MRD negative complete response, validating the combination therapy with daratumumab and dexamethasone.
  • Phase 3 EXCALIBER RRMM data for CELMoD ZENBEXUS demonstrated a doubling of median progression-free survival versus chemotherapy in lung cancer contexts.
Risk Factors
  • Simply Wall St reduced its fair value estimate from US$66.71 to US$65.25, driven by a revised long-term revenue growth assumption declining to 7.39% and a lower P/E multiple of 19.75x.
  • Wells Fargo highlights liver safety questions around admilparant, describing hepatic safety as a meaningful overhang that poses a risk to the program's development.
  • Interim Phase 1 Breakfree-2 data for zola cel in multiple sclerosis coincided with a patient death from septic pneumonia, which contributed to a roughly 2.5% share price decline.
  • Cautious analysts like Leerink, Morgan Stanley, and Cantor Fitzgerald express concerns around execution on key programs including admilparant, milvexian, and Cobenfy.
  • RBC notes that while the ALOFT-IPF efficacy profile is encouraging, it is confounding with limited differentiation expected from higher doses of admilparant.
Full Analysis
Simply Wall St has reduced its fair value estimate for Bristol-Myers Squibb (BMY) from US$66.71 to US$65.25, reflecting a more cautious outlook on the company's long-term revenue growth and valuation multiples. The analysis assumes a decline in long-term revenue growth of 7.39% compared to a prior estimate of 6.60%, while projecting a net profit margin increase to 21.52% from 20.59%. The assumed future P/E multiple has been lowered to 19.75x from 20.58x, with the discount rate remaining stable at 7.24%. Analyst sentiment remains highly divergent regarding BMY's pipeline and corporate strategy. Bullish firms like Piper Sandler, Jefferies, and Guggenheim cite strong potential in late-stage assets such as admilparant for idiopathic pulmonary fibrosis (IPF) and value from business development activity. Conversely, cautious analysts including Leerink, Morgan Stanley, and Cantor Fitzgerald express concerns over execution risks on key programs like milvexian and Cobenfy, while Wells Fargo highlights liver safety questions surrounding admilparant as a significant overhang. Recent clinical data has presented a mixed picture for the biopharmaceutical giant. Positive late-stage oncology readouts included Phase 3 results for izalontamab in breast and lung cancer showing significant risk reduction, alongside FDA approval support for CELMoD ZENBEXUS in multiple myeloma. However, interim Phase 1 data for zola cel in multiple sclerosis coincided with a patient death from septic pneumonia, which contributed to a roughly 2.5% share price decline. The company also expanded its AI and real-world data capabilities through new agreements with Tempus AI and Pathos AI.